MedTrace Logo

Feasibility and Pilot Study of a Rule-based Chatbot Application for Adolescents With Anxiety Symptoms

NCT05758935 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-08-28

No results posted yet for this study

Summary

The goal of this feasibility and pilot study is to investigate the feasibility and preliminary clinical effects of a new rule-based chatbot intervention for adolescents with anxiety symptoms. The main questions are:

* Is the intervention feasible for adolescents who are experiencing anxiety symptoms?
* How do the adolescents experience the use of the intervention?
* Does the intervention lead to a reduction in anxiety symptoms?
* Does the intervention lead to a clinically significant reliable improvement at functional level?

Conditions

Interventions

OTHER

Rule-based chatbot intervention with therapist-guidance

The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.

Sponsors & Collaborators

  • The Research Council of Norway

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Smiti Kahlon, PhD · Haukeland University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05758935 on ClinicalTrials.gov